Through a contractual agreement with Auckland Uniservices
Limited, the lab has already delivered a commercial drug
candidate called NNZ2566 for the New Zealand biotechnology
company Neuren Pharmaceuticals. NNZ2566 protects brain cells
from dying after traumatic head injury. With $18 million in
funding from the US Army, the drug is now in phase 2b human
clinical trials and is being tested in trauma centres around the
world.
If it goes to the market it will be the first drug for traumatic brain
injury, says Margaret. It will put The University of Auckland and
New Zealand on the international map as a world class hub for
drug discovery and development.
www.che.auckland.ac.nz/staffsites/BrimbleM/margaretbrimble
neuren link, page-2
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.17 |
Change
0.070(0.35%) |
Mkt cap ! $2.578B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.53 | $20.14 | $4.102M | 202.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 249 | $20.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.31 | 790 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |